IL125459A0 - Use of a thexaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization - Google Patents

Use of a thexaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization

Info

Publication number
IL125459A0
IL125459A0 IL12545998A IL12545998A IL125459A0 IL 125459 A0 IL125459 A0 IL 125459A0 IL 12545998 A IL12545998 A IL 12545998A IL 12545998 A IL12545998 A IL 12545998A IL 125459 A0 IL125459 A0 IL 125459A0
Authority
IL
Israel
Prior art keywords
thexaphyrin
medicament
preparation
chemotherapeutic agent
glycoprotein
Prior art date
Application number
IL12545998A
Other languages
English (en)
Original Assignee
Pharmacyclics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Inc filed Critical Pharmacyclics Inc
Publication of IL125459A0 publication Critical patent/IL125459A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL12545998A 1996-01-25 1998-07-22 Use of a thexaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization IL125459A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/591,318 US5776925A (en) 1996-01-25 1996-01-25 Methods for cancer chemosensitization

Publications (1)

Publication Number Publication Date
IL125459A0 true IL125459A0 (en) 1999-03-12

Family

ID=24366012

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12545998A IL125459A0 (en) 1996-01-25 1998-07-22 Use of a thexaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization

Country Status (13)

Country Link
US (1) US5776925A (cg-RX-API-DMAC7.html)
EP (1) EP0912196B9 (cg-RX-API-DMAC7.html)
JP (1) JP2000503989A (cg-RX-API-DMAC7.html)
KR (1) KR19990082024A (cg-RX-API-DMAC7.html)
CN (1) CN1093766C (cg-RX-API-DMAC7.html)
AT (1) ATE277637T1 (cg-RX-API-DMAC7.html)
AU (1) AU715025B2 (cg-RX-API-DMAC7.html)
DE (1) DE69730961T2 (cg-RX-API-DMAC7.html)
ES (1) ES2227671T3 (cg-RX-API-DMAC7.html)
IL (1) IL125459A0 (cg-RX-API-DMAC7.html)
NO (1) NO983429L (cg-RX-API-DMAC7.html)
NZ (1) NZ331513A (cg-RX-API-DMAC7.html)
WO (1) WO1997026915A1 (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US6482436B1 (en) 1993-01-29 2002-11-19 Ferx Incorporated Magnetically responsive composition
US6200547B1 (en) * 1994-01-26 2001-03-13 Ferx Incorporated Magnetically responsive compositions for carrying biologically active substances and methods of production and use
US5969111A (en) * 1994-04-14 1999-10-19 Board Of Regents, The University Of Texas System Texaphyrins substituted with imidazole are provided
RU2106146C1 (ru) 1995-07-17 1998-03-10 Институт элементоорганических соединений РАН Средство для подавления опухолевого роста
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
JPH10279502A (ja) * 1997-03-31 1998-10-20 Katsuro Tachibana 光感受性物質の励起方法
US6022526A (en) * 1997-07-30 2000-02-08 Pharmacyclics, Inc. Use of texaphyrins in detection of melanin and melanin metabolites diagnostic of melanotic melanoma
ATE376824T1 (de) 1999-01-13 2007-11-15 Alchemia Oncology Pty Ltd Verwendung von hyaluronan zur herstellung eines medikaments zur erhöhung der wirksamkeit von zytotoxischen arzneimitteln
HK1049787B (en) 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
WO2001032210A2 (en) * 1999-10-29 2001-05-10 Pharmacyclics, Inc. Compositions for treating atheroma and neoplastic tissue
US20030031676A1 (en) * 1999-10-29 2003-02-13 Pharmacyclics, Inc. Conjugate compounds for treating atheroma and other diseases
US7579338B2 (en) * 1999-10-29 2009-08-25 Pharmacyclics, Inc. Methods and compositions for treating atheroma, tumors and other neoplastic tissues
US20020077290A1 (en) * 2000-03-17 2002-06-20 Rama Bhatt Polyglutamic acid-camptothecin conjugates and methods of preparation
US9066919B2 (en) * 2000-07-14 2015-06-30 Alchemia Oncology Pty Limited Hyaluronan as a chemo-sensitizer in the treatment of cancer
AUPQ879500A0 (en) * 2000-07-14 2000-08-10 Meditech Research Limited Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US6638924B2 (en) 2000-08-30 2003-10-28 Pharmacyclics, Inc. Metallotexaphyrin derivatives
US7449454B2 (en) * 2000-08-30 2008-11-11 Pharmacyclics, Inc. Metallotexaphyrin derivatives
AU2001290580A1 (en) * 2000-08-30 2002-03-13 Pharmacyclics, Inc. Non-symmetric tripyrrannes in the synthesis of novel macrocycles
US20030188326A1 (en) 2000-11-03 2003-10-02 Dana Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof
AU2002236458A1 (en) * 2000-11-17 2002-05-27 Pharmacyclics, Inc. Texaphyrin coordination compounds and uses thereof
US20050013853A1 (en) * 2000-11-29 2005-01-20 Irit Gil-Ad Anti-proliferative drugs
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
US6630454B2 (en) 2001-09-10 2003-10-07 Ramot At Tel-Aviv University Ltd. Method and pharmaceutical composition for the treatment of cancer
WO2003039327A2 (en) 2001-11-02 2003-05-15 Dana-Farber Cancer Institute Methods and compositions for the diagnosis of cancer susceptibilities and defective dna repair mechanisms and treatment thereof
EP1463511A4 (en) * 2001-12-13 2005-09-28 Pharmacyclics Inc COMBINATORY ANTICANCER THERAPY
CN1615129A (zh) * 2001-12-13 2005-05-11 环状药物公司 影响神经病学进展的方法
US6984734B2 (en) 2002-02-26 2006-01-10 Board Of Regents, The University Of Texas System Cyclo[n]pyrroles and methods thereto
US6723750B2 (en) 2002-03-15 2004-04-20 Allergan, Inc. Photodynamic therapy for pre-melanomas
US20030224422A1 (en) * 2002-04-08 2003-12-04 St. Jude Children's Research Hospital, Inc. Pre-and post therapy gene expression profiling to identify drug targets
US20040010218A1 (en) * 2002-07-11 2004-01-15 Henderson Barbara W. Photodynamic therapy for the enhancement of vascular permeability to aid in drug delivery to diseased tissues
JP2004077714A (ja) * 2002-08-15 2004-03-11 Fuji Xerox Co Ltd 光走査装置
US7981928B2 (en) * 2002-09-05 2011-07-19 Nanodynamics, Inc. Chemotherapy method using x-rays
US20080063605A1 (en) * 2004-05-20 2008-03-13 Wai-Fung Cheong Method of Enhancing Visualization of Atherosclerotic Plaque
JP2006224318A (ja) * 2005-02-15 2006-08-31 Brother Ind Ltd インクジェット記録装置
JP4972929B2 (ja) * 2005-03-25 2012-07-11 ニプロ株式会社 放射線増感剤
EP1704870A1 (en) 2005-03-25 2006-09-27 Nipro Corporation Use of iron compounds as radiosensitizers
WO2007012133A1 (en) * 2005-07-27 2007-02-01 Alchemia Oncology Pty Limited Therapeutic protocols using hyaluronan
US8319625B2 (en) * 2005-09-01 2012-11-27 Simplexgrinnell Lp Fire alarm textual notification related application
EA013877B1 (ru) * 2005-09-07 2010-08-30 Алкемиа Онколоджи Пти Лимитед Терапевтические композиции, содержащие гиалуроновую кислоту и терапевтические антитела, а также способы лечения
US20070072838A1 (en) 2005-09-26 2007-03-29 Pharmacyclics, Inc. High-purity texaphyrin metal complexes
US20070078119A1 (en) * 2005-09-30 2007-04-05 Pharmacyclics, Inc. Storage system for texaphyrin pharmaceutical formulations
JP5590882B2 (ja) * 2006-06-26 2014-09-17 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 化学療法増感剤としてのシステインに富む酸性分泌タンパク質（ｓｐａｒｃ）
US8287839B2 (en) * 2006-12-04 2012-10-16 Brookhaven Science Associates, Llc Carboranylporphyrins and uses thereof
US8444953B2 (en) * 2007-03-22 2013-05-21 Brookhaven Science Associates, Llc Symmetric and asymmetric halogen-containing metallocarboranylporphyrins and uses thereof
US20080279781A1 (en) * 2007-05-10 2008-11-13 Brookhaven Science Associates, Llc Glycosylated Carboranylporphyrins and Uses Thereof
RU2438718C1 (ru) * 2010-06-18 2012-01-10 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ лечения сарком мягких тканей
US9662328B2 (en) 2010-11-29 2017-05-30 National Yang-Ming University Targeting human thymidylate kinase induces DNA repair toxicity in malignant tumor cells
TWI445696B (zh) 2010-11-29 2014-07-21 Univ Nat Yang Ming 標靶人類胸線核苷酸激酶誘導惡性腫瘤中的ｄｎａ修復毒性
EP3154541A4 (en) 2014-06-11 2017-12-20 Board of Regents, The University of Texas System Texaphyrin-pt(iv) conjugates and compositions for use in overcoming platinum resistance
EP3554475A4 (en) * 2016-12-13 2020-08-19 Health Research, Inc. PHOTODYNAMIC THERAPY (PDT) IN THE NEAR INFRARED (NIR) IN COMBINATION WITH CHEMOTHERAPY
CN116264824A (zh) 2020-08-14 2023-06-16 德克萨斯大学系统董事会 用于锰化学疗法、光声成像和光热疗法的德克萨卟啉衍生物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457183A (en) * 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5252720A (en) * 1989-03-06 1993-10-12 Board Of Regents, The University Of Texas System Metal complexes of water soluble texaphyrins
US4935498A (en) * 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5599923A (en) * 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5559207A (en) * 1989-03-06 1996-09-24 Board Of Regents, University Of Texas Texaphyrin metal complex mediated ester hydrolysis
US5607924A (en) * 1992-01-21 1997-03-04 Pharmacyclics, Inc. DNA photocleavage using texaphyrins
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
US5714328A (en) * 1995-06-07 1998-02-03 Board Of Regents, The University Of Texas System RNA photocleavage using texaphyrins

Also Published As

Publication number Publication date
CN1093766C (zh) 2002-11-06
EP0912196B1 (en) 2004-09-29
DE69730961T2 (de) 2005-11-24
EP0912196B9 (en) 2005-01-05
CN1213313A (zh) 1999-04-07
AU1833397A (en) 1997-08-20
EP0912196A1 (en) 1999-05-06
DE69730961D1 (de) 2004-11-04
KR19990082024A (ko) 1999-11-15
JP2000503989A (ja) 2000-04-04
US5776925A (en) 1998-07-07
ATE277637T1 (de) 2004-10-15
NZ331513A (en) 2001-10-26
AU715025B2 (en) 2000-01-13
ES2227671T3 (es) 2005-04-01
NO983429L (no) 1998-09-24
WO1997026915A1 (en) 1997-07-31
NO983429D0 (no) 1998-07-24
HK1018588A1 (en) 1999-12-30

Similar Documents

Publication Publication Date Title
IL125459A0 (en) Use of a thexaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization
舒良树 et al. Study of the high pressure metamorphic blueschist and its Late Proterozoic age in the eastern Jiangnan belt
IL222002B (en) A preparation of taxane for the treatment of cancer, restenosis and retinopathy
FI943445A0 (fi) Vesiliukoisten teksafyriinien metallikomplekseja
IL100942A0 (en) 2,4-diaminoquinazoline derivatives for enhancing antitumor activity
EP1229934A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER BY MEANS OF IMMUNO-CONJUGATES AND CHEMOTHERAPEUTIC AGENTS
IL99906A0 (en) Quinazoline derivatives for enhancing antitumor activity
IL134445A0 (en) A method of preventing or treating estrogen-dependent diseases and disorders
GB9415167D0 (en) Improvements relating to cancer therapy
ZA200703396B (en) Pegylated Liposomal Doxorubicin in combination with Ecteinascidin 743
NZ507570A (en) Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate
WO2004012662A3 (en) Improved treatment of cancer with glutamine
MY164077A (en) Compositions and uses of et743 for treating cancer
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
PT971710E (pt) Utilizacao de queleritrina e radiacao para terapia de tumores
NZ511150A (en) Non-fermented osmotic laxative for treating and preventing colorectal cancers
IL114382A0 (en) Cancer therapy using lymphotoxin
FI880944A7 (fi) Yhdistelmäterapia, jossa käytetään antituumori-immunotoksiineja yhdessä tuumorin nekroositekijän kanssa.
IL140580A0 (en) Isoflavonoid-based therapeutic composition intended to be used in the treatment of tumours with cytotoxic agents
WO2001034131A3 (en) Combination chemotherapy
AU4789099A (en) Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents
DK0980205T3 (da) Anvendelse af en kombination af TALL-104 celler med adriamycin eller cisplatin i behandlingen af maligniteter
CA2243392A1 (en) Use of a texaphyrin in the preparation of a medicament for use with a chemotherapeutic agent in cancer chemosensitization
NZ335125A (en) Carriers containing an etherlipid/complementarily shape lipid combination and therapeutic uses thereof
MY117808A (en) Cancer cell nuclease activator